MGMT and glioblastoma: The National Cancer Institute (NCI) is sponsoring a Phase 1 dose-escalation clinical trial to investigate the safety and tolerability of navtemadlin (KRT232/AMG232) as a monotherapy in recurrent GBM and in combination with RT for newly diagnosed GBM patients with an unmethylated MGMT promoter.